A randomized open label study comparing first-line treatment with bosentan or sildenafil in Pulmonary Arterial Hypertension (PAH)

Background: The efficacy of Bosentan (B) and Sildenafil (S) for the treatment of PAH appears to be similar according to specific randomized controlled trials. Limited data is available on the direct comparison between these two drugs. Objectives: to compare short-term hemodynamic and functional data and long-term outcome of PAH patients treated with first-line B (125 mg bid) or first-line S therapy (20 mg tid).